Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109873 | 0.90 | NR3C1 (0.49) | MEN1KMT2ANR3C1STSMAPT | |
| SCHEMBL6108331 | 0.83 | NR3C1 (0.46) | MEN1KMT2ANR3C1GPR119USP30 | |
| SCHEMBL6107131 | 0.83 | NR3C1 (0.46) | MEN1KMT2ANR3C1POLBUSP30 | |
| SCHEMBL5758733 | 0.81 | KDM4E (0.48) | KCNMA1NR3C1GPR119TP53FNTA | |
| SCHEMBL6107173 | 0.77 | F10 (0.50) | USP30 | |
| SCHEMBL25388020 | 0.77 | MEN1 (0.53) | MEN1KMT2AGPR119USP30STS | |
| SCHEMBL3156215 | 0.76 | KDM4E (0.45) | KCNMA1NR3C1KDM4EGAAHPGD | |
| SCHEMBL28463063 | 0.75 | PTPN2 (0.62) | MEN1KMT2AGPR119USP30STS | |
| SCHEMBL6106432 | 0.74 | F10 (0.52) | — | |
| SCHEMBL1307415 | 0.74 | GPR119 (0.60) | MEN1KMT2AGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6780878-B2 | ANTICOAGULANTS; CARDIOVASACULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6716855-B2 | INHIBITOR OF FACTOR XA; N1-(BENZOYL)-N2-(1-(4-PYRIDYL)PIPERIDIN-4-YL-METHYL)-1,2-BENZENDIAMINE HIGH BIOAVAILABILITY | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6710057-B2 | INHIBITORS OF FACTOR XA, AS ANTICOAGULANTS FOR PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20030212069-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
| US-6610704-B1 | Inhibit factor Xa | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | MEN1 2213/4885KMT2A 3180/4885KCNMA1 1137/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | MEN1 2213/4885KMT2A 3180/4885KCNMA1 1137/4885 |
| US-20030212069-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | MEN1 2213/4885KMT2A 3180/4885KCNMA1 1137/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | MEN1 2213/4885KMT2A 3180/4885KCNMA1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.